Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interleukin-26 (IL-26) is a novel anti-microbial peptide produced by T cells in response to staphylococcal enterotoxin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The genetic landscape of 87 ovarian germ cell tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Josef Chovanec
  • Iveta Selingerova
  • Kristina Greplova
  • Sofie Leisby Antonsen
  • Monika Nalezinska
  • Claus Høgdall
  • Estrid Høgdall
  • Erik Søgaard-Andersen
  • Kirsten M Jochumsen
  • Pavel Fabian
  • Dalibor Valik
  • Lenka Zdrazilova-Dubska
Vis graf over relationer

Background: We investigated the efficacy of circulating biomarkers together with histological grade and age to predict deep myometrial invasion (dMI) in endometrial cancer patients.

Methods: HE4ren was developed adjusting HE4 serum levels towards decreased glomerular filtration rate as quantified by the eGFR-EPI formula. Preoperative HE4, HE4ren, CA125, age, and grade were evaluated in the context of perioperative depth of myometrial invasion in endometrial cancer (EC) patients. Continuous and categorized models were developed by binary logistic regression for any-grade and for G1-or-G2 patients based on single-institution data from 120 EC patients and validated against multicentric data from 379 EC patients.

Results: In non-cancer individuals, serum HE4 levels increase log-linearly with reduced glomerular filtration of eGFR ≤ 90 ml/min/1.73 m2. HE4ren, adjusting HE4 serum levels to decreased eGFR, was calculated as follows: HE4ren = exp[ln(HE4) + 2.182 × (eGFR-90) × 10-2]. Serum HE4 but not HE4ren is correlated with age. Model with continuous HE4ren, age, and grade predicted dMI in G1-or-G2 EC patients with AUC = 0.833 and AUC = 0.715, respectively, in two validation sets. In a simplified categorical model for G1-or-G2 patients, risk factors were determined as grade 2, HE4ren ≥ 45 pmol/l, CA125 ≥ 35 U/ml, and age ≥ 60. Cumulation of weighted risk factors enabled classification of EC patients to low-risk or high-risk for dMI.

Conclusions: We have introduced the HE4ren formula, adjusting serum HE4 levels to reduced eGFR that enables quantification of time-dependent changes in HE4 production and elimination irrespective of age and renal function in women. Utilizing HE4ren improves performance of biomarker-based models for prediction of dMI in endometrial cancer patients.

OriginalsprogEngelsk
TidsskriftOncotarget
Vol/bind8
Udgave nummer64
Sider (fra-til)108213-108222
Antal sider10
ISSN1949-2553
DOI
StatusUdgivet - 8 dec. 2017

ID: 52665665